No edit summary |
|||
(12 intermediate revisions by 2 users not shown) | |||
Line 2: | Line 2: | ||
1. VP-16 |
1. VP-16 |
||
− | *[[Schaut]] |
+ | *[[Image:Tinysunfl.jpg]][[Schaut]], Nikki |
2. Vioxx |
2. Vioxx |
||
Line 8: | Line 8: | ||
3. Gleevec |
3. Gleevec |
||
− | *[[Schaut]] |
+ | *[[Image:Tinysunfl.jpg]][[Schaut]], Nikki - tumor started growing, stopped drug |
4. Celebrex |
4. Celebrex |
||
− | *[[Payne]] |
+ | *[[Image:Tinysunfl.jpg]][[Payne]], Steven |
⚫ | |||
5. Irinotecan and Temodar |
5. Irinotecan and Temodar |
||
− | *[[Ricardo]] |
||
+ | *[[Image:Tinysunfl.jpg]][[Ricardo]] |
||
⚫ | |||
+ | *[[Image:Tinysunfl.jpg]][[Robertson]],Nathan - stopped at 8 months, relapsed within 2 months |
||
+ | |||
+ | 6. Sutent |
||
+ | |||
+ | *[[Image:Tinysunfl.jpg]][[Ricardo]] |
||
+ | *[[Image:Tinysunfl.jpg]][[Robertson]],Nathan |
||
+ | *[[Image:Tinysunfl.jpg]][[Skurat]], Steven |
||
==Alternative and Complementary== |
==Alternative and Complementary== |
||
+ | [[Image:Tinysunfl.jpg]][[Braswell]], Christian |
||
− | 1. |
||
− | *[[Braswell]], Chris |
||
⚫ | |||
− | 2. |
||
⚫ | |||
==Clinical Studies== |
==Clinical Studies== |
Latest revision as of 20:02, 10 September 2010
Maintenance Drugs
1. VP-16
- Schaut, Nikki
2. Vioxx
- Orgel , Greg
3. Gleevec
- Schaut, Nikki - tumor started growing, stopped drug
4. Celebrex
5. Irinotecan and Temodar
6. Sutent
Alternative and Complementary
Braswell, Christian
Orantes, Meliza
Clinical Studies
http://www3.interscience.wiley.com/cgi-bin/abstract/112151892/ABSTRACT?CRETRY=1&SRETRY=0
Response to vinorelbine and low-dose cyclophosphamide chemotherapy in two patients with desmoplastic small round cell tumor Andrea Ferrari, MD 1 *, Federica Grosso, MD 2, Silvia Stacchiotti, MD 2, Cristina Meazza, MD 1, Elena Zaffignani, MD 1, Alfonso Marchianò, MD 3, Michela Casanova, MD 1 1Pediatric Oncology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy 2Adult Sarcoma Medical Oncology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy 3Radiology Department, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy
email: Andrea Ferrari (andrea.ferrari@istitutotumori.mi.it)
- Correspondence to Andrea Ferrari, Pediatric Oncology Unit, Istituto Nazionale Tumori, Via G. Venezian, 1-20133 Milano MI, Italy.
Keywords desmoplastic small round cell tumor • low-dose cyclophosphamide • metronomic therapy • vinorelbine
Abstract
We report two cases of abdominal desmoplastic small round cell tumor (DSRCT) that showed a clinical response to the vinorelbine/low-dose cyclophosphamide combination that has been claimed to be effective for rhabdomyosarcoma. This observation may prompt further investigation into the activity of such a regimen in DSRCT patients with recurrent or refractory disease, with a view to a possible future role as maintenance therapy in controlling minimal residual disease in patients who achieve complete remission with intensive induction multimodality therapy. Pediatr Blood Cancer © 2005 Wiley-Liss, Inc.
DSRCT References
[BACK]